Oncobiologics, Inc. Series B Warrant
ONSIZ
ONSIZ was delisted on the 16th of May, 2018.
10 hedge funds and large institutions have $60K invested in Oncobiologics, Inc. Series B Warrant in 2017 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 0 increasing their positions, 4 reducing their positions, and 2 closing their positions.
17% less funds holding
Funds holding: 12 → 10 (-2)
50% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 2
89% less capital invested
Capital invested by funds: $557K → $60K (-$497K)
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VF
Virtu Financial
New York
|
+$788 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PA
Perceptive Advisors
New York
|
-$42K |
| 2 |
SM
Sabby Management
Miami Beach,
Florida
|
-$15.8K |
| 3 |
MIM
Monashee Investment Management
Boston,
Massachusetts
|
-$1.65K |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$217 |
| 5 |
Morgan Stanley
New York
|
-$181 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
CAM
1
Cormorant Asset Management
Boston,
Massachusetts
| $21K | – | – | – |
|
|
SM
2
Sabby Management
Miami Beach,
Florida
| $13K | -$15.8K | -240,606 | -48% |
|
|
ACA
3
Avoro Capital Advisors
New York
| $12K | – | – | – |
|
|
ACP
4
Acuta Capital Partners
Redwood City,
California
| $5K | – | – | – |
|
|
PC
5
PointState Capital
New York
| $5K | – | – | – |
|
6
Millennium Management
New York
| $2K | -$59 | -900 | -2% |
|
|
MIM
7
Monashee Investment Management
Boston,
Massachusetts
| $1K | -$1.65K | -25,000 | Closed |
|
|
VF
8
Virtu Financial
New York
| $1K | +$788 | +11,980 | New |
|
|
PA
9
Perceptive Advisors
New York
| – | -$42K | -462,500 | Closed |
|
|
10
UBS Group
Zurich,
Switzerland
| – | -$217 | -3,300 | -81% |
|
|
11
Morgan Stanley
New York
| – | -$181 | -2,750 | -31% |
|
ONSIZ Hedge Fund Activity: Q3 2017 in Review
10 of the 4,012 institutional investors tracked by Wall St. Rank reported a position in Oncobiologics, Inc. Series B Warrant (ONSIZ) for Q3 2017, worth a combined $60K — down 89% from $557K a quarter earlier.
Sellers outnumbered buyers: 2 funds closed out of ONSIZ and 1 opened new positions — a net loss of 1 holder — while 4 trimmed existing stakes and 0 added.
The largest buyer was Virtu Financial, opening a new position worth an estimated $788. The largest seller was Perceptive Advisors, exiting entirely with an estimated $42K sold.
- 10 institutional investors held Oncobiologics, Inc. Series B Warrant (ONSIZ) as of Q3 2017, down from 12 in Q2 2017.
- Funds reported $60K of Oncobiologics, Inc. Series B Warrant stock for Q3 2017, down 89% quarter-over-quarter.
- 1 fund opened new Oncobiologics, Inc. Series B Warrant positions in Q3 2017 and 2 closed out, a net change of -1 holder.
- The largest Oncobiologics, Inc. Series B Warrant buyer in Q3 2017 was Virtu Financial, an estimated $788 added.
- The largest Oncobiologics, Inc. Series B Warrant seller in Q3 2017 was Perceptive Advisors, an estimated $42K sold.
Based on aggregated 13F filings for Q3 2017.